Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2004 Jun;5(6):1243-56.

Delaying surgery with chemotherapy for osteosarcoma of the extremities.

Author information

1
Universitätsklinikum Münster, Cooperative Osteosarkomstudiengruppe (COSS), Klinik und Poliklinik für Kinderheilkunde und Jugendmedizin, Pädiatrische Hämatologie und Onkologie, Münster, Germany. coss@uni-muenster.de

Abstract

Osteosarcoma is the most frequent primary cancer of bone. When treated by surgery alone, it is almost invariably followed by metastatic dissemination and death. This dismal prognosis can be improved dramatically by including chemotherapy in an interdisciplinary regimen. Today, two-thirds of patients with localised extremity primaries can achieve long-term survival with such intensive multimodal therapy. This article provides a summary overview of current pharmacotherapy in osteosarcoma of the extremities, focussing on the approach of preoperative 'neoadjuvant' chemotherapy and thus, the potential benefits and pitfalls of delaying surgery. Prospective, multi-institutional trials are essential in guaranteeing that as many patients as possible can benefit from modern, efficacious interdisciplinary therapeutic regimens and that further progress can be made.

PMID:
15163270
DOI:
10.1517/14656566.5.6.1243
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center